Outcomes and patients’ perspectives of transition from paediatric to adult care in inflammatory bowel disease

Table 3 Inflammatory bowel disease outcomes of transition n (%)

	Transition cohort	Non-transition cohort	P value
Medication (self-reported)
5-aminosalicylic acid	19 (41)	14 (41)	1.00
Sulfasalazine
Mesalazine
Immunomodulator	30 (65)	25 (71)	0.63
Azathioprine/6	27	24
Mercaptopurine
Methotrexate	3	1
Biologic therapy (anti-TNF)	8 (17)	9 (26)	0.42
Infliximab	6	5
Adalimumab	2	4
Non-compliance	3 (7)	4 (11)	0.46
Perianal disease	9 (20)	8 (24)	0.79
Complications (Perforation, bowel obstruction, stricture)	12 (26)	5 (14)	0.27
Surgery (Resection +/- stoma, fistula with seton)	15 (33) (9 prior to transition)	10 (29)	0.81
Number of hospital admissions per patient (median)
During paediatric care	3.2	N/A
During adult care	1.5	2.1	0.67
Number of flares requiring steroids per patient (median)
Since transition	0.5	N/A
During last year	0.5	1	0.31
Extra intestinal manifestations of IBD (Arthropathy/Cutaneous/Ocular/Hepatobiliary/Metabolic bone disease)1	6 (14)	8 (24)	0.37
IBD symptoms
Physical	39 (85)	33 (94)	0.29
Psychological	16 (35)	16 (46)	0.36
Social	29 (63)	26 (76)	0.23
MDT utilisation
General Practitioner	34 (74)	25 (69)	0.80
Psychologist	2 (4)	3 (8)	0.65
Dietician	9 (20)	7 (19)	1.00
Colorectal surgeon	12 (26)	11 (31)	0.80
IBD nurse	11 (24)	19 (25)	0.01
Relationship status
Single	22 (48)	17 (49)	1.00
In a relationship	20 (43)	12 (34)	0.49
Married	4 (9)	6 (17)	0.32
Divorced	0 (0)	0 (0)	1.00
Education (level completed)
Primary	43 (100)	35 (100)	1.00
Secondary	38 (88)	27 (77)	0.23
Tertiary	19 (41)	5 (14)	0.01
TAFE (Technical and further education)	8 (17)	12 (34)	0.12
Apprenticeship/trade	6 (13)	7 (20)	0.54
Employment
Currently employed	35 (76)	21 (60)	0.15
Full-time employment	21 (60)	11 (52)	0.59
Average hours worked/week	29.8	34.2

¹Mouth ulcers were omitted. IBD: Inflammatory bowel disease.